CURR Cure Pharmaceutical Holding

CURE Pharmaceutical [OTCQB:CURR] Expands Cannabis Extraction Patents, Adding Support for CBG for Therapeutic Solutions

CURE Pharmaceutical [OTCQB:CURR] Expands Cannabis Extraction Patents, Adding Support for CBG for Therapeutic Solutions

Equipment manufacturers, cannabis processors and drug developers can license CURE’s patented methods for optimal extraction of cannabinoids

LOS ANGELES, April 21, 2020 (GLOBE NEWSWIRE) -- (OTC: CURR), an innovative drug delivery and development company, today announced the issuance of two U.S. Patents: No. 10,639,339 and 10,624,940. These patents represent an expansion of CURE’s existing “product by process” patents for obtaining multiple unique cannabis concentrates using super critical fluid extraction (SCFE). These include cannabinoid concentrates enriched in cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG), a non-psychoactive cannabinoid which has shown promising therapeutic activity in animal studies in areas such as inflammatory bowel disease, cancer and infectious diseases.

“Adding CBG to our SCFE patent portfolio aligns with the latest research and early clinical evidence supporting its therapeutic benefit,” said Rob Davidson, CEO of CURE Pharmaceutical. “We continue to expand this portfolio to the latest commercial applications for SCFE, providing our patent licensees and their customers expanded IP rights.”

CURE is granting , cannabis processing companies and cannabinoid drug developers licenses to its portfolio of issued and pending process and composition patents for isolating cannabinoids using an advanced SCFE technology utilizing carbon dioxide as the solvent. While the patents cover the incorporation of cannabis extracts into multiple dosage forms, CURE has retained all rights to applying these methods in oral thin films.

The two patents cover the extraction and purification of cannabis plant material, as well as subsequent processing of cannabis extracts for drug formulation. This extraction and fractioning of bioactive cannabinoid molecules allows for the integration of these molecules into dosage forms.

About CURE Pharmaceutical

CURE Pharmaceutical® is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage forms and delivery systems. CURE has an FDA- and DEA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform. CUREform includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S, Canada, Israel, and other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.

For more information about CURE Pharmaceutical, please visit its website at .

This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Media Contact:

Paulo Acuna



310-824-9000

EN
21/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cure Pharmaceutical Holding

 PRESS RELEASE

Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased...

Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments New Marketing Programs Showing Encouraging Early Results OXNARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Holding Corp. (OTC: CURR) (“CURE”), a proprietary broad platform and wellness technology company, today announced results for the quarter ended June 30, 2022. Key operational highlights included the following: Gross revenue of $1.6 million reflected an increase of 31.2% from Q1 to Q2 with f...

 PRESS RELEASE

CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Boar...

CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years of public company experience. Rob Costantino brings a unique combination of decades of financial expertise, investing experience and shareholder advocacy, operational experience, and many years of negotiating success in closing multi-bi...

 PRESS RELEASE

CURE Pharmaceutical Provided Full Corporate Update on Recent Sharehold...

CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call OXNARD, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022. On the recorded call/webcast, the executive management team provided details on the recent $20 million non-dilutive sale of a portion of its product and intellectual property portfolio and provided a full business update. As discussed on the call, the Company intends to execute on its strat...

 PRESS RELEASE

CURE Pharmaceutical Announces the Appointment of New Board Member

CURE Pharmaceutical Announces the Appointment of New Board Member Gerald Bagg brings deep understanding of CPG to CURE OXNARD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced the appointment of Gerald Bagg to its board of directors. This strategic addition adds depth in CPG and advertising and brings the number of board members to five. “With the increased prominence of CURE’s wholly-owned subsidiary, The Sera Labs, Inc., and the efforts we are undertaking to grow existing brands as well as develo...

 PRESS RELEASE

CURE Pharmaceutical Announces Teleconference With Investors

CURE Pharmaceutical Announces Teleconference With Investors Updates on Recent Transaction and Business will be Provided OXNARD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company will be hosting a teleconference with management on Wednesday, August 3, 2022, at 5:00 pm Eastern Time to discuss the recent $20 million non-dilutive sale of a small portion of its product and intellectual property portfolio and to provide a business update. As a business update we would like to note the fol...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch